Daily Market Reports | 11:25 AM
An additional news report on the recommendation, valuation, forecast and opinion changes and updates for ASX-listed equities.
In addition to The Australian Broker Call Report, which is published and updated daily (Mon-Fri), FNArena has now added The Australian Broker Call *Extra* Edition, featuring additional sources of research and insights on ASX-listed stocks, also enlarging the number of stocks that make up the FNArena universe.
One key difference is the *Extra* Edition will not be updated daily, but merely "regularly" depending on availability of suitable quality content. As such, the *Extra* Edition tries to build a bridge between daily updates via the Australian Broker Call Report and ad hoc news stories, that are not always timely for investors hungry for the next information update.
Investors using the *Extra* Edition as a source of input for their own share market research should thus take into account that information after publication may not be up to date, or yet awaiting another update by FNArena's team of journalists.
Similar to The Australian Broker Call Report, this *Extra* Edition includes concise but limited reviews of research recently published by Stockbrokers and other experts, which should be considered as information concerning likely market behaviour rather than advice on the securities mentioned. Do not act on the contents of this Report without first reading the important information included at the end of this Report.
The Australian Broker Call *Extra* Edition is a summary that has been prepared independently of the sources identified. Readers will check the full text of the recommendations and consult a Licenced Advisor before making any investment decision.
The copyright of this Report is owned by the publisher. Readers will not copy, forward or disseminate this Report to any other person. For more vital information about the sources included, see the bottom of this Report.
COMPANIES DISCUSSED IN THIS ISSUE
Click on a symbol for fast access.
The number next to the symbol represents the number of brokers covering it for this report -(if more than 1)
AIA AIZ BET BPT CIA CMA COL COV DUG DVP DXB EDV ELD EMR HRZ ILU IPD JIN KCN KMD LRK LTR NAB NEC OBM ORG PLS PXA REG RMD (2) TPW WAF
DVP DEVELOP GLOBAL LIMITED
Industrial Metals - Overnight Price: $5.49
Canaccord Genuity rates ((DVP)) as Upgrade to Speculative Buy from Hold (1) -
Commissioning at Woodlawn continues, with Develop Global reiterating it is on track to reach nameplate capacity of 850ktpa this quarter. Dec Q Revenue of $55.5m was in line with Canaccord Genuity and steady quarter on quarter.
During the quarter, Develop Global was awarded a five-year, $200m underground development contract to establish the Waihi North Gold Project owned by OceanaGold.
Management highlighted it was assessing and progressing a substantial volume of tenders, reflecting favourable market conditions. Target rises to $5.70 from $5.05, upgrade to Speculative Buy from Hold.
This report was published on February 2, 2026.
Target price is $5.70 Current Price is $5.49 Difference: $0.21
If DVP meets the Canaccord Genuity target it will return approximately 4% (excluding dividends, fees and charges).
The company's fiscal year ends in June.
Forecast for FY26:
Canaccord Genuity forecasts a full year FY26 dividend of 0.00 cents and EPS of 17.00 cents.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is 32.29.
Forecast for FY27:
Canaccord Genuity forecasts a full year FY27 dividend of 0.00 cents and EPS of 66.00 cents.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is 8.32.
Market Sentiment: 1.0
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
DXB DIMERIX LIMITED
Pharmaceuticals & Biotech/Lifesciences - Overnight Price: $0.53
Petra Capital rates ((DXB)) as Buy (1) -
Petra Capital notes Dimerix's 2Q26 4C showed cash of $38.5m, with operating cash outflow easing to $11.1m q/q but still above expectations, partly reflecting the absence of a circa $2m R&D rebate and residual one-off costs.
The broker expects burn to moderate now that recruitment for the ACTION 3 FSGS trial is complete and highlights Dimerix remains well funded to progress the trial and commercial readiness.
Focus remains on upcoming FDA feedback, which will determine the timing of a blinded statistical powering analysis and whether a 12-month accelerated approval pathway for DMX-200 remains viable.
Petra Capital retains a Buy rating and $1.46 target, with forecasts under review.
This report was published on February 1, 2026.
Target price is $1.46 Current Price is $0.53 Difference: $0.93
If DXB meets the Petra Capital target it will return approximately 175% (excluding dividends, fees and charges).
The company's fiscal year ends in June.
Forecast for FY26:
Petra Capital forecasts a full year FY26 dividend of 0.00 cents.
Forecast for FY27:
Petra Capital forecasts a full year FY27 dividend of 0.00 cents.
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
EDV ENDEAVOUR GROUP LIMITED
Food, Beverages & Tobacco - Overnight Price: $3.66
Jarden rates ((EDV)) as Underweight (4) -
Jarden's FMCG survey results were most positive for Woolworths Group ((WOW)) but Coles Group ((COL)) is still widely expected to outperform in 2026, a view the broker sees as increasingly at risk.
Overall sentiment was more pessimistic than expected, reflecting regulatory risk, easing inflation and more value-conscious consumers amid heightened competition.
The broker favours FMCG and category leaders, while flagging pricing risks for Coles and Endeavour Group in 2H26.
Underweight rating for Endeavour. Target price $3.20.
This report was published on January 30, 2026.
Target price is $3.20 Current Price is $3.66 Difference: minus $0.46 (current price is over target).
If EDV meets the Jarden target it will return approximately minus 13% (excluding dividends, fees and charges - negative figures indicate an expected loss).
Current consensus price target is $3.72, suggesting upside of 2.0%(ex-dividends)
The company's fiscal year ends in June.
Forecast for FY26:
Jarden forecasts a full year FY26 EPS of 21.40 cents.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is 17.10.How do these forecasts compare to market consensus projections?
Current consensus EPS estimate is 22.1, implying annual growth of -7.1%.
Current consensus DPS estimate is 16.4, implying a prospective dividend yield of 4.5%.
Current consensus EPS estimate suggests the PER is 16.5.
Forecast for FY27:
Jarden forecasts a full year FY27 EPS of 23.80 cents.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is 15.38.How do these forecasts compare to market consensus projections?
Current consensus EPS estimate is 24.0, implying annual growth of 8.6%.
Current consensus DPS estimate is 17.9, implying a prospective dividend yield of 4.9%.
Current consensus EPS estimate suggests the PER is 15.2.
Market Sentiment: 0.0
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
The full story is for FNArena subscribers only. To read the full story plus enjoy a free two-week trial to our service SIGN UP HERE
If you already had your free trial, why not join as a paying subscriber? CLICK HERE